Every 424B that Anteris Technologies Global Corp. (AVR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow AVR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVR filings page.
Anteris Technologies Global Corp. (AVR) filed a prospectus supplement to its Form S-1 registration statement covering up to 9,103,796 shares of common stock that may be sold from time to time by selling stockholders. The supplement incorporates a recent Current Report on Form 8-K.
The 8-K reports that, on September 4, 2026, Anteris appointed Brent Moen as Chief Financial Officer, effective September 11, 2026, under an employment agreement providing a $475,000 annual base salary, a target bonus of up to 50% of base salary (prorated for 2026), and eligibility for long-term equity incentives, including a 2026 stock option award with a target grant date value of $500,000 that vests in three equal annual installments and has a 10-year term. If terminated without cause, he is eligible for nine months of base salary continuation and up to nine months of COBRA premium reimbursement, subject to a release. Former CFO Matthew McDonnell will transition to Head of Australia, continuing under his existing compensation and benefit arrangements.
Anteris Technologies Global Corp. is a development-stage cardiac device company advancing its DurAVR® transcatheter heart valve system through a global pivotal Trial intended to support FDA Premarket Approval and CE Mark. Recruitment is underway in Europe, the United States and France, supported by IDE clearance and U.S. Medicare reimbursement eligibility for the study.
For the three months ended June 30, 2026, net sales were $1.0 million, up from $0.6 million, largely from regenerative tissue products, while the company recorded a net loss attributable to stockholders of $29.1 million. For the first half of 2026, net sales were $1.5 million and the net loss was $52.1 million, driven mainly by R&D expenses of $40.8 million and selling, general and administrative expenses of $15.3 million as clinical, manufacturing and headcount investments increased.
Liquidity strengthened significantly: cash, cash equivalents and restricted cash totaled $260.9 million at June 30, 2026, following a January 2026 public offering and a strategic private placement to Medtronic generating approximately $320.0 million in gross proceeds, plus an established $250.0 million at-the-market equity program. Management believes existing cash resources will fund operations for at least 12 months, though recurring losses are expected to continue. Previously identified material weaknesses in internal control over financial reporting remain under remediation and caused disclosure controls and procedures to be deemed not effective as of June 30, 2026.
Anteris Technologies Global Corp. entered into a Sales Agreement with TD Securities (USA) LLC on May 22, 2026 to sell shares of its common stock in an at-the-market offering with an aggregate offering price of up to $250,000,000 through TD Cowen. This prospectus supplement dated May 26, 2026 updates the Registration Statement and Prospectus related to up to 9,103,796 shares of common stock that may be offered by selling stockholders and attaches the Form 8-K describing the Sales Agreement.
The Sales Agreement permits sales on Nasdaq, negotiated transactions and block trades, and sets TD Cowen’s selling commission at 3.0% of gross proceeds. Net proceeds are intended primarily for development of the DurAVR® Transcatheter Heart Valve System and for working capital and general corporate purposes.
Anteris Technologies Global Corp. filed a prospectus supplement establishing an at-the-market offering program to sell up to $250,000,000 of its common stock through TD Securities (USA) LLC (TD Cowen) as sales agent. Sales may occur from time to time on Nasdaq or other trading venues; TD Cowen will receive 3.0% of gross proceeds as compensation.
The supplement uses an example price of $9.00 per share (last reported sale on May 21, 2026) and illustrates issuance of 27,777,777 shares, resulting in up to 125,009,831 shares outstanding under that example. Net proceeds are intended primarily for continued development of the DurAVR® THV System, with remaining amounts for working capital and general corporate purposes.
Anteris Technologies Global Corp. files a prospectus supplement to update its shelf prospectus and to register 9,103,796 shares of common stock for resale by the selling stockholders identified in the Prospectus. The supplement attaches the Company’s Form 10-Q and Form 8-K and states the registered shares “may be offered for sale by the selling stockholders” pursuant to the Prospectus.
For context, the number of shares outstanding was 97,342,203 as of May 11, 2026. The supplement amends and supersedes portions of the Prospectus where indicated and should be read together with the Prospectus.
Anteris Technologies Global Corp. files a Prospectus Supplement to its Form S-1 registering up to 9,103,796 shares of common stock for resale by selling stockholders. The supplement attaches a Form 8-K disclosing that the company elected to discontinue further development contributions to v2vmedtech, inc., triggering termination of a related Development Agreement upon payment of a $400,000 break fee. The company states it does not expect these actions to have a material adverse effect on consolidated financial position or liquidity.
Anteris Technologies Global Corp. files a prospectus supplement updating its Registration Statement to cover the resale of up to 9,103,796 shares of Common Stock by the selling stockholders named in the Prospectus. The supplement attaches a Form 8-K reporting a new lease.
The Form 8-K discloses a lease through a wholly owned subsidiary for approximately 181,436 square feet in Brooklyn Park, Minnesota, with an initial term from September 1, 2026 to August 31, 2037. The lease specifies an initial monthly minimum rent of $152,708.63, contractual rent abatements (first three months fully abated, succeeding nine months partially abated), annual escalations, and payment of taxes and operating expenses. The lease description is qualified by the full lease to be filed as an exhibit to the Company’s Form 10-Q.
Anteris Technologies Global Corp. registers 9,103,796 shares for resale by selling stockholders. The registration covers up to 9,103,796 shares of Common Stock, comprised of 2,346,936 Shares, 2,346,936 Common Stock Warrant Shares, 2,079,962 CDI Shares and 2,329,962 CDI Warrant Shares.
The prospectus states the Company will not receive proceeds from secondary resales but may receive up to $40.4 million in aggregate gross proceeds if the Warrants are exercised. The filing describes the 2025 Private Placement, the 2026 Public Offering and the Medtronic private placement, and includes selling stockholder tables and plan of distribution methods.
Anteris Technologies Global Corp. has a resale registration covering up to 9,103,796 shares of common stock that may be sold by existing stockholders under a prior Form S-1. This prospectus supplement adds information from recent current reports, including a new capital raise. The company entered into an underwritten public offering of 34,782,609 shares, plus an additional 5,217,391 shares sold under the underwriters’ option, at $5.75 per share, and a concurrent private placement of 15,652,173 shares at the same price to a Medtronic subsidiary. Combined gross proceeds from the offering and private placement are expected to be approximately $320 million, before fees and expenses. Anteris plans to use the cash to fund its DurAVR THV pivotal trial, expand manufacturing, support v2vmedtech research and development, and for working capital and general corporate purposes.
Anteris Technologies Global Corp. is issuing 34,782,609 shares of common stock at $5.75 per share in a primary public offering on Nasdaq. The deal is expected to raise approximately $189.8 million in gross proceeds before expenses, with net proceeds estimated at about $187.4 million, or $215.6 million if underwriters fully exercise a 5,217,391‑share option. Concurrently, a Medtronic plc subsidiary has agreed to buy 15,652,173 additional shares in a private placement at the same price, with expected net proceeds of about $84.4 million that are not registered in this prospectus.
After the offering and private placement, Anteris expects to have 86,497,152 shares outstanding, including CDIs. Proceeds, together with existing cash, will fund the PARADIGM pivotal trial of the DurAVR THV system for severe aortic stenosis, expand manufacturing capacity, and support R&D, including for v2vmedtech, plus working capital. The company is a development‑stage structural heart business with preliminary cash of about $12.6 million as of December 31, 2025 and an auditor going‑concern explanatory paragraph, and it acknowledges that investors in this offering will experience immediate dilution of $2.50 per share.
Anteris Technologies Global Corp. is registering $200,000,000 of common stock in a primary offering. The company has also granted underwriters a 30-day option to buy up to an additional $30,000,000 of common stock. Concurrently, a Covidien subsidiary of Medtronic may purchase up to $90.0 million of common stock in a private placement at the same price as this offering, for a stake between 16.0% and 19.99% of shares outstanding after the deals close.
Anteris develops the DurAVR THV System for treating severe aortic stenosis and is running the global PARADIGM pivotal trial following FDA IDE and initial European approvals. The company remains a development-stage business with recurring losses and preliminary cash and cash equivalents of about $12.6 million as of December 31, 2025, and its auditors have raised substantial doubt about its ability to continue as a going concern. Proceeds from this offering and the private placement are intended to fund PARADIGM trial execution, manufacturing expansion, R&D for v2vmedtech and general corporate purposes, and Anteris is also exploring up to $100 million of additional debt financing.
Anteris Technologies Global Corp. filed a prospectus supplement linked to its Form S-1 registration statement covering up to 9,103,796 shares of common stock that may be sold from time to time by selling stockholders. The supplement incorporates information from a newly filed Current Report on Form 8-K.
The attached 8-K notes that on December 13, 2025 (December 14, 2025 in Australia), Stephen Denaro resigned, with immediate effect, from the Company’s Board of Directors as a Class II director, and his resignation was not due to any disagreement over operations, policies or practices. He will continue as corporate secretary of Anteris Technologies Pty Ltd and as a director of that and other Australian subsidiaries. The Company’s common stock trades on Nasdaq under the symbol AVR, which closed at $4.98 per share on December 12, 2025.